Diabetes research and clinical practice最新文献

{"title":"Comparative effectiveness of different glycemic criteria for the diagnosis of gestational diabetes mellitus: a target trial emulation","authors":"Zhijuan Cao ,&nbsp;Tao Wang ,&nbsp;Xiaoxian Qu ,&nbsp;Jiaqi Dong ,&nbsp;Shengyu Wu ,&nbsp;Yirong Bao ,&nbsp;Jue Li ,&nbsp;Hao Ying","doi":"10.1016/j.diabres.2025.112283","DOIUrl":"10.1016/j.diabres.2025.112283","url":null,"abstract":"<div><h3>Aims</h3><div>There’s no scientific consensus on the best way to diagnose gestational diabetes mellitus (GDM) globally. This study uses target trial emulation to assess different glycemic criteria for GDM diagnosis.</div></div><div><h3>Methods</h3><div>38,995 singleton − pregnant women who took a 75 − g oral glucose tolerance test at 24–32 weeks of gestation were involved. Cloning, censoring, and inverse probability weighting were applied for emulation. Log − binomial regression estimated the effects of various criteria on adverse birth outcomes, and statistical significance and estimates were evaluated.</div></div><div><h3>Results</h3><div>4,539 women (11.6 %) were diagnosed with lower criteria, 2,463 (6.3 %) with intermediate, and 1,744 (4.5 %) with higher criteria. The proportion of large − for − gestational − age (LGA) infants was 7.12 % in the lower criteria group and 8.26 % in the higher criteria group (RR = 0.96, 95 % CI: 0.90 to 1.02). Similar LGA risks were found between intermediate and lower criteria. All outcomes showed statistical significance and agreement with targeted trials.</div></div><div><h3>Conclusions</h3><div>Lower glycemic criteria increased GDM diagnosis 2.53 − fold compared to higher criteria and 1.80 − fold relative to intermediate criteria, yet risks of LGA newborns and other issues remained unchanged.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112283"},"PeriodicalIF":6.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144146884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microvascular complications in prediabetes: a systematic review & meta-analysis","authors":"Sama Thiab ,&nbsp;Taim Akhal ,&nbsp;Meriem Akeblersane ,&nbsp;Heet Sheth ,&nbsp;Stephen L. Atkin ,&nbsp;Alexandra E. Butler","doi":"10.1016/j.diabres.2025.112261","DOIUrl":"10.1016/j.diabres.2025.112261","url":null,"abstract":"<div><h3>Aims</h3><div>Prediabetes prevalence is increasing with a risk of developing microvascular complications. The American Diabetes Association (ADA) definition is a hemoglobin A1c(HbA1c) of 5.7 %–6.4 % (39–46 mmol/mol) versus the International Experts Committee (IEC) range of 6.0–6.4 % (42–46 mmol/mol). We aimed to determine whether a prediabetic HbA1c or fasting blood glucose (FBG) cut-off exists, above which individuals exhibit increased microvascular complications.</div></div><div><h3>Methods</h3><div>All prediabetes studies in Embase, MEDLINE, Scopus, Cochrane, CINAHL databases from 1990–May 2023 reporting retinopathy, nephropathy, and/or neuropathy included.</div></div><div><h3>Results</h3><div>21,215 studies identified, 35 analyzed.<!--> <!-->Prevalence and incidence of retinopathy was significantly higher by ADA versus IEC criteria (Weighted Mean Difference 2.37 [2.31,2.43] and 1.32 [1.25,1.40], respectively). Receiver Operator Curves for IEC criteria: sensitivity 65.3% specificity 88.0% for retinopathy, AUC 0.88; for ADA criteria at 5.9%: sensitivity 77.5%, specificity 78.4%, AUC 0.73. No studies reported nephropathy/neuropathy by IEC criteria; nephropathy prevalence 1.0%-15.0% for HbA1c and FBG criteria.</div></div><div><h3>Conclusions</h3><div>Prediabetes ADA criteria (HbA1c 5.7–6.4 %) identified significantly more retinopathy than IEC criteria (HbA1c 6.0–6.4 %), suggesting that ADA criteria are preferable for early retinopathy detection and clinical retinal screening may be considered at HbA1c ≥ 5.7 %. Insufficient studies on the prevalence of nephropathy and neuropathy in prediabetes were available.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112261"},"PeriodicalIF":6.1,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144139155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International Diabetes Federation membership grows to 251 diabetes associations.","authors":"","doi":"10.1016/j.diabres.2025.112281","DOIUrl":"https://doi.org/10.1016/j.diabres.2025.112281","url":null,"abstract":"","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"112281"},"PeriodicalIF":6.1,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting the benefits vs risk profile of sodium-glucose co-transporter inhibitor use in type 1 diabetes Part A: Benefits of sodium-glucose co-transporter inhibitor use in type 1 diabetes.","authors":"Jennifer Ngan, David N O'Neal, Melissa H Lee, Yee Wen Kong, Richard J MacIsaac","doi":"10.1016/j.diabres.2025.112278","DOIUrl":"https://doi.org/10.1016/j.diabres.2025.112278","url":null,"abstract":"<p><p>There has been increasing research into non-insulin therapies to assist people living with type 1 diabetes (T1D) improve their glucose control and to help prevent the development and progression of vascular and kidney complications. In particular, the sodium-glucose co-transporter (SGLT) inhibitor class of medication has received attention as an adjunctive therapy in T1D. These medications have an established and important role in the management of type 2 diabetes, heart failure and chronic kidney disease. Unfortunately, SGLT inhibitors, especially when taken during periods of fasting or intercurrent illness, can precipitate diabetic ketoacidosis (DKA). Considering the above, SGLT inhibitors have failed to obtain an indication for use in the setting of T1D. Here we review the potential glycaemic, cardiovascular and kidney benefits of SGLT inhibitors for people with T1D.</p>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"112278"},"PeriodicalIF":6.1,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the comment on: High fasting plasma glucose in early pregnancy and adverse pregnancy outcomes in Chinese women","authors":"Ming Gao ,&nbsp;Ninghua Li ,&nbsp;Hui Wang ,&nbsp;David Simmons ,&nbsp;Xilin Yang","doi":"10.1016/j.diabres.2025.112271","DOIUrl":"10.1016/j.diabres.2025.112271","url":null,"abstract":"","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112271"},"PeriodicalIF":6.1,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0","authors":"Graham D. Ogle ,&nbsp;Fei Wang ,&nbsp;Aveni Haynes ,&nbsp;Gabriel A. Gregory ,&nbsp;Thomas W. King ,&nbsp;Kylie Deng ,&nbsp;Dana Dabelea ,&nbsp;Steven James ,&nbsp;Alicia J. Jenkins ,&nbsp;Xia Li ,&nbsp;Ronald C.W. Ma ,&nbsp;David M. Maahs ,&nbsp;Richard A. Oram ,&nbsp;Catherine Pihoker ,&nbsp;Jannet Svensson ,&nbsp;Zhiguang Zhou ,&nbsp;Dianna J. Magliano ,&nbsp;Jayanthi Maniam","doi":"10.1016/j.diabres.2025.112277","DOIUrl":"10.1016/j.diabres.2025.112277","url":null,"abstract":"<div><h3>Aims</h3><div>Globally, symptomatic type 1 diabetes (T1D) prevalence varies markedly. The International Diabetes Federation 11th<!--> <!-->Edition Atlas/T1D Index Version 3.0 estimated 2025 numbers for 202 countries/territories (“countries”), and projected to<!--> <!-->2040.</div></div><div><h3>Methods</h3><div>The T1D Index model, a Markov model with sub-models for incidence-over-time, adult incidence, and mortality-over-time, was updated with recent population-based T1D incidence, mortality and prevalence studies. For countries without studies, data were extrapolated from countries with similar<!--> <!-->settings.</div></div><div><h3>Results</h3><div>There are estimated 9.5 million people living with T1D globally (compared to 8.4 million in 2021, a 13 % increase), with 1.0 million of these aged 0–14, and 0.8 million aged 15–19 years. In lower-income countries, prevalent cases increased by 20 % from 1.8 million in 2021 to 2.1 million in 2025. Incident cases in 2025 are an estimated 513,000 (164,000 aged 0–14 and 58,000 aged 15–19 years), with incidence increasing by 2.4 % in the last year. Premature deaths are estimated at 174,000, with 17.2 % of these due to non-diagnosis soon after clinical onset. The estimated remaining life expectancy of a 10-year-old child diagnosed with T1D in 2025 varies between countries from 6 to 66 years. There are still no data available for 119 countries. The projected<!--> <!-->T1D population for 2040 is estimated to be14.7 million.</div></div><div><h3>Conclusions</h3><div>The number of global T1D cases is rising quickly, especially in lower-income settings, due to increasing diagnosed incidence, falling mortality and ageing, and population growth. Contemporary data are unavailable for over 50% of all countries, highlighting need for epidemiological studies.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112277"},"PeriodicalIF":6.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Higher population density protects from type 1 diabetes? Dissecting the literature through meta-analysis.","authors":"Susanna Tall, Inka Sylgren, Suvi M Virtanen, Mikael Knip","doi":"10.1016/j.diabres.2025.112272","DOIUrl":"https://doi.org/10.1016/j.diabres.2025.112272","url":null,"abstract":"<p><p>Even though urbanization has been repeatedly established in relation to risk of type 1 diabetes in scientific research, meta-analyses or systematic reviews revealing overall trends in the literature have not been published. We performed a meta-analysis to investigate the association between population density and risk of type 1 diabetes and aimed to include all available literature up to February 22, 2025. Eighteen studies in 14 countries with 82,493 type 1 diabetes cases were included in the meta-analysis. We found evidence of an inverse association between population density and risk of type 1 diabetes (risk ratio = 0.86 [95 % CI: 0.81, 0.92], P < 0.001, N = 18, adjusted for all available confounders). However, variation in the association between studies and geographic areas was observed. Risk of bias due to uncontrolled confounding in observational studies can never be excluded. In addition, we found high unexplained effect size variation among the included studies in our meta-analysis. Our results are not in line with the view that urbanization would systematically increase the risk of type 1 diabetes and highlight the variability of the association among geographic regions. More studies outside Europe are needed to further establish the potential association.</p>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"112272"},"PeriodicalIF":6.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of depression on healing outcomes in people with diabetes-related foot ulcers: A systematic review","authors":"Abeer M. Al-Smadi ,&nbsp;Kathleen Finlayson ,&nbsp;Brooke Andrew ,&nbsp;Christina Parker","doi":"10.1016/j.diabres.2025.112275","DOIUrl":"10.1016/j.diabres.2025.112275","url":null,"abstract":"<div><div>This systematic review examined the impact of depression on healing outcomes among people with diabetes-related foot ulcers (DFUs). A comprehensive search of MEDLINE, APA PsycINFO, CINAHL, Embase, and The Cochrane Library was conducted from inception (1976) to 11 March 2024 to identify eligible studies. The Mixed Methods Appraisal Tool (MMAT) was used to assess study quality, and a narrative synthesis was conducted. We identified 1403 articles, of which 11 were included in the final analysis and included a total of 1392 participants with DFUs. The included studies used diagnostic interviews and screening tools to assess depression, and healing outcomes were described as healed ulcer, change in ulcer size, and/or changes in ulcer severity classification tool scores. Of the 11 studies, five studies (45.5 %) found that there was a significant negative impact (or association) of depression on healing outcomes of DFUs. On the other hand, six studies (54.5 %) showed there was no significant impact or association. Three studies were considered high quality, four studies medium quality, and four studies low quality. Depression may have a significant negative impact on healing outcomes in people with DFUs. However, the existing evidence is still unclear, and further high-quality studies are needed to investigate this impact.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112275"},"PeriodicalIF":6.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical effectiveness of tirzepatide for patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study","authors":"Jheng-Yan Wu ,&nbsp;Kuan-Jui Tseng ,&nbsp;Chia-Li Kao ,&nbsp;Kuo-Chuan Hung ,&nbsp;Tsung Yu ,&nbsp;Yu-Min Lin","doi":"10.1016/j.diabres.2025.112279","DOIUrl":"10.1016/j.diabres.2025.112279","url":null,"abstract":"<div><h3>Aim</h3><div>This study aimed to evaluate whether tirzepatide is associated with a reduced atrial fibrillation (AF) burden in patients with type 2 diabetes (T2D).</div></div><div><h3>Methods</h3><div>A retrospective cohort study was conducted using the TriNetX database. Adults with both AF and T2D diagnosed between January 2022 and February 2025 were included. The primary outcome was a composite of cardioversion, intravenous antiarrhythmic drug use, and AF ablation. Secondary outcomes included each component of the composite, heart failure, ischemic stroke, and all-cause mortality. Propensity score matching and Cox models were used. Subgroup analyses were conducted based on AF type, coronary artery disease, chronic kidney disease, heart failure, and obesity.</div></div><div><h3>Results</h3><div>After matching, 11,194 patients were analyzed. Tirzepatide use was associated with a significantly lower risk of the primary outcome (HR: 0.65; 95 % CI: 0.55–0.76; P &lt; 0.001). Significant findings were also observed across all secondary outcomes, including cardioversion, intravenous antiarrhythmic therapy, atrial fibrillation ablation, heart failure, ischemic stroke, and all-cause mortality. These associations remained consistent across prespecified subgroups and multiple sensitivity analyses.</div></div><div><h3>Conclusion</h3><div>Tirzepatide was significantly associated with reduced AF burden in patients with T2D and AF. These findings suggest a potential therapeutic role, supporting further prospective evaluation.</div><div>Condensed abstract</div><div>Tirzepatide, a dual GLP-1/GIP receptor agonist, has shown metabolic and cardiovascular benefits, but its impact on AF burden remains unclear. Using the TriNetX database, this study analyzed 11,194 patients with AF and T2D and found that tirzepatide use was significantly associated with a lower two-year risk of cardioversion, intravenous antiarrhythmic drug use, and AF ablation (HR: 0.65; 95 % CI: 0.55–0.76; P &lt; 0.001). These findings suggest that tirzepatide may offer therapeutic benefits in this high-risk population, warranting further investigation through randomized clinical trials.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112279"},"PeriodicalIF":6.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autonomic function and hemodynamic changes in type 2 diabetes: insights into sympathetic activation and vascular stiffness","authors":"Larissa Morete Caieiro da Costa ,&nbsp;Tatiana Palotta Minari ,&nbsp;Luciana Pellegrini Pisani ,&nbsp;Tatiane de Azevedo Rubio ,&nbsp;Louise Bounalume Tácito Yugar ,&nbsp;Luis Gustavo Sedenho-Prado ,&nbsp;Milene Ribeiro ,&nbsp;Lúcia Helena Bonalume Tacito ,&nbsp;Luciana Neves Cosenso-Martin ,&nbsp;Antônio Carlos Pires ,&nbsp;Heitor Moreno ,&nbsp;José Fernando Vilela-Martin ,&nbsp;Juan Carlos Yugar-Toledo","doi":"10.1016/j.diabres.2025.112266","DOIUrl":"10.1016/j.diabres.2025.112266","url":null,"abstract":"<div><h3>Aims</h3><div>This study aimed to investigate the relationship between autonomic function, arterial stiffness, and vascular compliance in patients with type 2 diabetes (T2D).</div></div><div><h3>Methods</h3><div>Eighty-one T2D patients were divided into two groups based on disease duration: &lt;10 years (N = 50) and &gt;10 years (N = 31). Autonomic function was assessed via heart rate variability, and vascular hemodynamics via pulse wave velocity (PWV). Linear and multivariate regression analyses explored associations between autonomic function and vascular parameters.</div></div><div><h3>Results</h3><div>Female participants predominated, accounting for 60 % in the &lt;10 years group and 64.5 % in the &gt;10 years group. Comorbidities were present in 67.7 % of the &lt;10 years group and 70 % of the &gt;10 years group. Biochemical differences were minimal, except for a significant albumin/creatinine ratio in the &gt;10 years group (p = 0.007). Central hemodynamics showed no significant differences, but sympathetic activity correlated with diastolic blood pressure (DBP) during wakefulness (r = 0.45, p = 0.003).</div></div><div><h3>Conclusions</h3><div>While no direct correlation was found between arterial stiffness and autonomic function, increased sympathetic activation was linked to higher DBP. Early screening, lifestyle modifications, and targeted treatments could improve patient outcomes and T2D management.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112266"},"PeriodicalIF":6.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}